Zimmer Biomet(US:ZBH) ZACKSยท2025-02-04 15:20Core Insights - Zimmer Biomet (ZBH) is expected to report quarterly earnings of $2.30 per share, reflecting a 4.6% increase year-over-year [1] - Revenue forecasts stand at $2.01 billion, indicating a 3.7% year-over-year growth [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3] Revenue Breakdown - 'Net Sales- Knees' is estimated at $839.93 million, a 5.2% increase from the prior year [5] - 'Net Sales- Other' is projected at $174.21 million, reflecting a 5.2% decrease year-over-year [5] - 'Net Sales- S.E.T' is expected to reach $475.72 million, indicating a 5% increase [5] Regional Sales Estimates - 'Net Sales- Hips' is forecasted at $525.56 million, a 4.1% increase from the previous year [6] - 'Net Sales- Knees- International' is estimated at $347.47 million, showing a 6.3% increase [6] - 'Net Sales- Hips- International' is projected at $252.20 million, reflecting a 4.4% increase [7] U.S. vs. International Sales - 'Net Sales- United States' is expected to reach $1.19 billion, a 5.3% increase year-over-year [8] - 'Net Sales- International' is forecasted at $836.84 million, indicating a 3.1% increase [8] Stock Performance - Over the past month, Zimmer shares have returned +4.4%, outperforming the Zacks S&P 500 composite's +1% [9] - Zimmer currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [9]